Nosocomial Pneumonia Pipeline Market Research Report 2022: Comprehensive Insights About 13+ Companies and 13+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nosocomial Pneumonia – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

The “Nosocomial pneumonia – Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Nosocomial pneumonia pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Nosocomial pneumonia pipeline landscape is provided which includes the disease overview and Nosocomial pneumonia treatment guidelines. The assessment part of the report embraces, in depth Nosocomial pneumonia commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nosocomial pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Nosocomial pneumonia R&D. The therapies under development are focused on novel approaches to treat/improve Nosocomial pneumonia.

Nosocomial pneumonia Emerging Drugs Chapters

This segment of the Nosocomial pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nosocomial pneumonia Emerging Drugs

Suvratoxumab: AstraZeneca

Suvratoxumab is a human immunoglobulin G1 kappa monoclonal antibody with an extended half-life, targeted pore-forming ? toxin of Staphylococcus aureus. The drug is in Phase II clinical studies for the treatment of Nosocomial Pneumonia.

Tosatoxumab: Aridis Pharmaceuticals

Tosatoxumab (AR-301, Salvecin) is an intravenous, broadly active, human monoclonal antibody (IgG1?) that targets the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin. The drug is in Phase III clinical developmental studies for the treatment of Nosocomial Pneumonia.

CMTX 101: Clarametyx Biosciences

Clarametyx’s pioneering therapy, CMTX-101, is a monoclonal antibody designed to rapidly collapse bacterial biofilms – protective shields that coat bacterial pathogens and help make them resistant to the effects of antibiotics and immune response. CMTX-101 targets a region of DNABII binding proteins that are essentially identical across all pathogenic bacteria. Bacterial DNABII proteins stabilize and maintain the integrity of bacterial biofilms. Precisely targeting this region on the DNABII proteins rapidly collapses biofilms, rendering the bacteria more vulnerable to the effects of antibiotics and the immune system. Currently, the drug is in Pre-Clinical stage of development for the treatment of nosocomial pneumonia.

Rifabutin: BioVersys

Rifabutin (BV100) has a novel mode of action addressing carbapenem resistant Acinetobacter baumannii (CRAB) lung and blood stream infections. Currently the drug is in Phase I of stage of development for the treatment of Nosocomial Pneumonia.

Nosocomial pneumonia: Therapeutic Assessment

This segment of the report provides insights about the different Nosocomial pneumonia drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Nosocomial Pneumonia

There are approx. 13+ key companies which are developing the therapies for Nosocomial Pneumonia. The companies which have their Nosocomial pneumonia drug candidates in the most advanced stage, i.e. phase III include, Aridis Pharmaceuticals.

Key Players

• AstraZeneca
• Aridis Pharmaceuticals
• BioVersys
• Clarametyx Biosciences
• GlaxoSmithKline
• Regeneron Pharmaceuticals
• Spexis
• Nabriva Therapeutics
• Hoth Therapeutics
• Helperby Therapeutics

Key Products

• Rifabutin
• CMTX 101
• Suvratoxumab
• Tosatoxumab
• Murepavadin
• Panobacumab
• Lefamulin
• AR 401
• HT-006
• HY-012B5

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/fvupki

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900